We seek to engage in ongoing dialogue with a broad range of industry and corporate experts to develop unique and differentiated sources of information. We look to identify investment alternatives that may be mispriced or misunderstood by the broader investing community.
Our strategies also specialize in creating detailed alternative scenario analysis that can highlight potential investment opportunities. Our evolving focus is on presenting those investment cases to institutional investors in a clear and concise fashion.
Head of Research
Rommel Dionisio is the Head of Research, and also covers stocks in the Consumer, Technology & Special Situations sectors. He brings over 25 years of experience as a sell-side equity analyst, having previously worked at Merrill Lynch, FBR, and Wedbush Morgan. Mr. Dionisio is a nine-time honoree by the Thomson Reuters StarMine analyst ranking, a three-time All-Star on the Wall Street Journal’s Best of the Street annual survey, and a two-time honoree on Forbes’ Best Brokerage Analysts ranking. He frequently appears on CNBC, Bloomberg TV, and Fox Business, and is often quoted by numerous financial publications around the world. Mr. Dionisio received his BA and MBA degrees from Duke University, where he was the P. Huber Hanes, Jr. Scholar of his class.
DR. DAVID BOUCHEY
Head of Healthcare Equity Research
Dr. David Bouchey joins Aegis Capital as Head of Equity Healthcare Research. Prior to joining Aegis, Dr. Bouchey worked as a healthcare analyst at C.E. Unterberg, Towbin, LLC, Canaccord Adams Inc. and RBC Capital Markets Corp. focusing on small and mid-cap companies. Dr. Bouchey spent 16 years as a research scientist at different University labs before becoming a sell-side analyst, where he spent over 20 years identifying and evaluating emerging biotechnology and medical device companies. During his career, Dr. Bouchey analyzed hundreds of companies and over a hundred clinical trials, FDA applications and product launches. Dr. Bouchey was recognized for his research analysis by Institutional Investor Magazine, which designated him a Double Home Run Hitter, the only analyst to achieve that status since 1995. Dr. Bouchey also spent 8 years as an industry consultant and executive at Pharmacyclics and Capital Genomics, as well as the CEO of AntiSomaGen, a start-up biotechnology company. Dr. Bouchey holds a PhD in cell and molecular biology from the University of Virginia, an MBA in finance and monetary economics from the University of Kentucky, an MS in Virology from the University of Kentucky and a BS in Microbiology and Public Health from Michigan State University. He holds FINRA Series 7, 86 and 87 licenses.